AGENDA AT A GLANCE
8:30
Registration & Coffee
8:55
Chairman’s Welcome Note
The Future of Antibody Engineering: Designing Next-Generation Therapeutics
9:00
Advancing Antibody Engineering for the Next Generation of Therapeutics
- Innovations in antibody discovery and engineering
- Optimising affinity, specificity and developability
- Bispecific and multispecific antibody design strategies
- Leveraging AI and computational tools in antibody engineering
9:25
Reserved for Solution Provider
9:50
Panel: From Discovery to Development: Building Better Antibody Therapeutics
- Identifying and selecting optimal antibody candidates with strong therapeutic potential
- Recognizing and overcoming developability challenges early in the discovery process
- Translating promising research findings into successful clinical development programs
- Engineering antibodies for robust manufacturability, scalability, and quality control
- Integrating discovery, development, and regulatory considerations to accelerate therapeutic success
10:15
Networking Break
Process Scale-Up and Manufacturing Readiness for Antibodies, Bioconjugates and ADCs
11:00
De-Risking Process Scale-Up for Antibodies, Bioconjugates and ADCs from Lab to GMP Manufacturing
- Key challenges in scaling biologics and ADC processes from bench to GMP production
- Managing process variability and ensuring comparability across scale-up stages
- Identifying and controlling critical process parameters (CPPs) during scale-up
- Strategies to reduce manufacturing risks and improve yield consistency
11:25
Reserved for Service Provider
11:50
Building Manufacturing-Ready Platforms for Clinical to Commercial Transition in Biologics and ADCs
- Designing scalable and robust platform processes for antibodies and ADCs
- Integrating process development with manufacturing requirements early in development
- Ensuring tech transfer readiness across internal sites and external CDMOs
- Aligning MSAT, CMC, and operations for seamless commercialisation
12:15
Lunch Break
Purification Strategies and Analytical Characterization for Antibodies, Bioconjugates and ADCs
13:15
Optimising Purification Strategies for High-Purity Antibodies, Bioconjugates and ADCs
- Designing robust purification workflows for complex biologics and ADC molecules
- Managing aggregation, charge variants, and impurity clearance during purification
- Improving yield and recovery while maintaining product consistency and quality
- Scaling purification processes from development to GMP manufacturing
14:00
Reserved for Solution Provider
14:25
Advanced Analytical Characterisation to Ensure Quality, Stability and Comparability of Biologics and ADCs
- Defining and monitoring Critical Quality Attributes (CQAs) across development stages
- Applying advanced analytical tools for structural and functional characterisation of ADCs and antibodies
- Ensuring batch-to-batch comparability from clinical to commercial scale
- Integrating analytical data into CMC strategies for regulatory and manufacturing readiness
14:50
Networking Break
16:00
Roundtable Discussions
- What Will Define the Next Generation of Antibody-Based Therapeutics?
- How Can Industry Accelerate ADC Development While Managing Cost and Complexity?
- Are Current Manufacturing Technologies Ready for the Future ADC Pipeline?
- Balancing Innovation, Scalability and Commercial Viability in Antibody Therapeutics
16:30
Key Takeaways
16:45
Drink Reception & End of Day 1
8:30
Registration & Coffee
8:55
Chairman’s Welcome Note
ADC Design Excellence: Linkers, Payloads and Conjugation Technologies
9:00
Designing Next-Generation ADCs: Optimising Linker–Payload Selection for Therapeutic Performance
- Principles of linker design: stability in circulation vs controlled payload release
- Selecting optimal payloads for different ADC mechanisms of action and indications
- Balancing efficacy, safety, and therapeutic index in ADC design
- Overcoming challenges in linker–payload compatibility and stability
9:25
Reserved for Solution Provider
9:50
Advances in Conjugation Technologies for Site-Specific and Highly Stable ADC Development
- Evolution of conjugation methods: chemical vs enzymatic vs engineered site-specific approaches
- Improving homogeneity and drug-to-antibody ratio (DAR) control
- Enhancing stability and manufacturability of ADC constructs
- Addressing scale-up and reproducibility challenges in conjugation processes
10:15
Networking Break
Formulation and Stability of ADCs
10:45
Designing Stable ADC Formulations: Balancing Efficacy, Safety and Structural Integrity
- Key formulation challenges in maintaining ADC stability and payload integrity
- Managing linker–payload stability under physiological and storage conditions
- Optimising buffer systems, excipients, and formulation conditions for ADCs
- Preventing aggregation, deconjugation, and degradation during development and storage
11:10
Reserved for Service Provider
11:35
Panel Discussion - Overcoming Stability Challenges in ADC Development Across Clinical to Commercial Scale
- Understanding degradation pathways specific to ADCs (chemical, physical, and biological)
- Establishing stability-indicating analytical methods for ADCs
- Ensuring consistency of stability profiles during scale-up and tech transfer
- Designing robust storage and cold-chain strategies for global distribution
12:00
Lunch Break
ADC Manufacturing Excellence: Conjugation, Drug Product and Fill-Finish
13:00
Robust and Scalable ADC Conjugation Strategies for Commercial Manufacturing
- Establishing consistent and reproducible conjugation processes for ADC manufacturing
- Controlling Drug-to-Antibody Ratio (DAR) and product heterogeneity at scale
- Managing process variability in chemical vs site-specific conjugation methods
- Ensuring scalability and tech transfer readiness from clinical to commercial production
13:45
ADC Drug Product Development: Ensuring Stability, Compatibility and Performance
- Designing stable ADC drug product formulations for long-term storage and distribution
- Addressing aggregation, deconjugation and degradation risks in ADC formulations
- Selecting optimal excipients and buffer systems for complex biologics
- Integrating analytical controls to ensure product quality and consistency
14:10
Networking Break
14:40
Aseptic Fill-Finish and Manufacturing Control for Highly Potent ADCs
- Overcoming aseptic processing challenges for highly potent ADC molecules
- Ensuring sterility assurance and contamination control during fill-finish operations
- Maintaining product integrity during filling, handling and packaging
- Strengthening GMP compliance and process controls for global ADC supply chains
Technology Transfer, Supply Chain and Commercial Manufacturing Excellence
15:05
Successful Technology Transfer Strategies for Antibody and ADC Manufacturing
- Managing technology transfer risks by identifying critical process parameters early and implementing robust control strategies
- Strengthening cross-functional collaboration between R&D, process development, manufacturing, and quality teams to ensure seamless knowledge transfer
- Maintaining consistent product quality and process performance throughout transfer through thorough documentation and comparability assessments
- Accelerating manufacturing readiness by streamlining scale-up activities, validation processes, and regulatory alignment for faster deployment
15:30
Building Resilient Supply Chains for Antibody and ADC Products
- Managing complex global supply networks
- Ensuring raw material security
- Outsourcing and CDMO partnerships
- Preparing supply chains for future growth
15:55
Chairman's Closing Remarks
16:00
END OF CONFERENCE
